This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Blue Cross moves to dismiss US antitrust claims over spinal fusions

( June 25, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Blue Cross Blue Shield told a US federal judge that TranS1 cannot show that it conspired to keep it out of the market. BCBS argued that “the complaint does not allege that a single commercial health insurer in the US covers TranS1 spinal fusion services; yet, based on nothing more than BCBSA’s publication of non-binding, template medical policies, the complaint alleges ‘an explicit collusive agreement to shut out AxiaLIF from the relevant spinal fusion markets in violation of federal antitrust laws.’”See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections